REPLICEL LIFE SCIENCES INC.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the six months ended September 30, 2023 and 2022
...
Related Keywords
China , Canada , United States , Vancouver , British Columbia , Taiwan , Hong Kong , Macau , Chinese , Canadian , Lee Buckler , David Hall , Replicel Life Sciences Inc , Company Stock Option Plan , Company Or Replicel , International Financial Reporting Standards , Shiseido Company , Company Options , Venture Exchange , Party Transactions , Bus Partnership , Trichoscience Innovations Inc , International Accounting Standards Board , Mainpointe Pharmaceuticals , Technology Transfer Agreement , China Health Industry Co , While The Company , National Instrument , Given The Company , Canadian Dollars , Interim Financial , Consolidated Interim Statements , Cel Life Sciences , Ontario Business Corporations Act , Replicel Life Sciences , Trichoscience Innovations , Accounting Estimates , Collaboration Agreement , Health Industry , Replicel Injector Product Line , Interpretations Effective , Collaborative Agreement , Greater China , Mainland China , Contract Liability , License Fee , Share Purchase Agreement , Distribution Agreement , Cel Injector Product , Royalty Participation Agreement , Chief Technology Officer , Discounted Market Price , Aging Skin , Chronic Tendinosis , Treatment Androgenic Alopecia , Replicel Injector Product , Payback Period , Issue Date , Required Redemption Date , Redemption Price , Novel Coronavirus , Canada Emergency Business Account , Government Grants , Government Assistance , Government Grant , News Release , Preferred Shares , Each Warrant , Stock Option Plans , Stock Option Plan , Risk Management , Shiseido Company Limited , Markets ,
comparemela.com © 2020. All Rights Reserved.